Hospitals proving themselves wrong about prices
Whenever a new report claims hospitals are charging too much, a stock set of defenses comes out. But hospitals are cutting prices and expenses as we speak, undermining those arguments.
Life Science & Biotech
Articles
Are employers ready to limit workers’ choice of doctor?
The real test of so-called narrow network health plans will come not with Obamacare's exchanges, but with employers, who control a far bigger slice of the health benefits pie and have been highly reluctant to limit their workers' choice of hospitals and doctors.
New institute aims to attract 100 research scientists to Indiana
The $360 million initiative will be formally launched on Thursday by Gov. Mike Pence, executives of five major life sciences companies and officials of the state’s research universities.
Swedish shows stark contrast with Braly
One month into Joe Swedish's tenure as CEO of WellPoint Inc., he and the communications staff set up an interview with me. That was quite different from my experience with Angela Braly, who declined all of my interview requests in her 63 months as CEO.
A dose of reality about the business of health care
Welcome to The Dose, a blog about the business of health care. As your host, J.K. Wall, I'll be writing about the most interesting new developments I see at hospitals, doctors, insurers, employers, patients, drugmakers, device companies and medical researchers around Indianapolis and around the country.
Think again: Why Obama’s disclosure of hospital charges won’t help you
In the first post on my new blog, The Dose, I explain why the recently released Medicare charge data are meaningless for everyone but uninsured patients.
Report: Roche mulls sale of blood-glucose monitor business
Roche Diagnostics Corp. is considering a sale of its blood-glucose meter business, a move that would cast uncertainty over the nearly 1,000 people working for its diabetes business in Indianapolis.
PINCUS: State needs better life sciences startup ecosystem
Indiana’s life sciences sector is mostly composed of legacy companies.
Mobile health apps could cut into state companies’ market share
The future of Indiana’s sprawling health care and life sciences industry might be threatened by an unlikely source: smartphone apps.
PANEL: Life sciences will see radically different future
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues of venture capital, digital health innovations and research university entrepreneurship.
Panel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.
The following is an unedited transcript of the discussion.
New seed fund aims to make Indiana a hotbed for digital health startups
Infuse Accelerator hopes to make early-stage investments in 12 to 15 companies a year.
Lilly suing J&J for patent rights in Alzheimer’s drug race
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
Dow AgroSciences grows sales, earnings to new heights
Record sales for seeds and new crop protection products helped boost revenue 14 percent at Indianapolis-based Dow AgroSciences LLC in its new fiscal year.
Lilly seeks $30.6M in tax breaks on downtown projects
Indianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to a new manufacturing plant and improvements to existing operations downtown.
IU medical school’s push to launch startups bears fruit
The Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity the school has never seen before.
Expected revenue slump spurs Lilly to cut sales force
The Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for the loss of patent protection on two of its best-selling drugs.